Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus

Clin Gastroenterol Hepatol. 2019 Sep;17(10):1929-1936.e1. doi: 10.1016/j.cgh.2018.10.007. Epub 2018 Oct 9.

Abstract

In areas where hepatitis B virus (HBV) is endemic, mother-to-child transmission (MTCT) is the major route of infection of children. Blocking MTCT of HBV therefore would reduce its prevalence. The China Foundation of Hepatitis Prevention and Control organized a team of specialists in infectious diseases, hepatology, immunology, obstetrics, and public health to develop an algorithm for interrupting MTCT of HBV, based on the most recent hepatitis B guidelines and latest evidence. This algorithm comprises 10 steps and has been adopted in clinical practice in China. Four aspects (screening, antiviral intervention during pregnancy, immunoprophylaxis, and postvaccination serologic testing) are the core components of preventing MTCT. Although the combination of passive and active immunization in newborns of hepatitis B surface antigen-positive mothers reduces MTCT of HBV, this immunoprophylaxis cannot completely eradicate MTCT. In the past decade, administration of antiviral agents to pregnant women has been shown to be safe and effective in reducing MTCT of HBV in combination with immunoprophylaxis. Aiming to achieve zero MTCT, this algorithm recommends the use of antivirals during pregnancy by women with high viral loads. Preventing MTCT is key to achieving the goal of eliminating HBV as a public health threat by 2030. Implementation and enhancement of the standardized algorithm for pregnant women with chronic HBV infection and their infants is urgently needed to prevent MTCT.

Keywords: Antiviral Therapy; CFHPC; Neonate; Vaccine.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Algorithms
  • Antiviral Agents / therapeutic use*
  • Breast Feeding
  • Female
  • Hepatitis B Vaccines / therapeutic use*
  • Hepatitis B virus / immunology
  • Hepatitis B, Chronic / diagnosis
  • Hepatitis B, Chronic / drug therapy*
  • Hepatitis B, Chronic / prevention & control
  • Humans
  • Immunization, Passive
  • Immunoglobulins / therapeutic use*
  • Immunologic Factors / therapeutic use*
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical / prevention & control*
  • Mass Screening
  • Practice Guidelines as Topic
  • Pregnancy
  • Pregnancy Complications, Infectious / diagnosis
  • Pregnancy Complications, Infectious / drug therapy*
  • Tenofovir / therapeutic use
  • Vaccination
  • Viral Load

Substances

  • Antiviral Agents
  • Hepatitis B Vaccines
  • Immunoglobulins
  • Immunologic Factors
  • Tenofovir